Did changes in drug reimbursement after the medicare modernization act affect chemotherapy prescribing?

Journal of Clinical Oncology

Volumn 32, Issue 36, 2014, Pages 4042-4049

  Hornbrook, Mark C ^a   Malin, Jennifer ^b   Weeks, Jane C ^c,d   Makgoeng, Solomon B ^f   Keating, Nancy L ^c,e   Potosky, Arnold L ^f  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; TOPOTECAN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; PRESCRIPTION DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; COLORECTAL CANCER; FEMALE; HUMAN; LAW; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; PRESCRIPTION; REIMBURSEMENT; SMALL CELL LUNG CANCER; VERY ELDERLY; COLORECTAL NEOPLASMS; DRUG UTILIZATION; ECONOMICS; INTEGRATED HEALTH CARE SYSTEM; LEGISLATION AND JURISPRUDENCE; LUNG NEOPLASMS; MEDICAL FEE; MIDDLE AGED; UNITED STATES;

AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DELIVERY OF HEALTH CARE, INTEGRATED; DRUG UTILIZATION; FEE-FOR-SERVICE PLANS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEDICARE PART D; MIDDLE AGED; PRESCRIPTION DRUGS; REIMBURSEMENT MECHANISMS; UNITED STATES;

EID: 84919779430     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.6780     Document Type: Article

References (24)

1. General Accounting Office (GAO): Medicare payments to oncologists. Report No. GAO-05-142R. Washington, DC, GAO, 2005
2. Medicare Payment Advisory Commission (MEDPAC): Report to the Congress: Effects of Medicare Payment Changes on Oncology Services. Washington, DC, MEDPAC, 2006
3. Ayanian JZ, Chrischilles EA, Fletcher RH, et al: Understanding cancer treatment and outcomes: The Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol 22:2992-2996, 2004
4. Malin JL, Ko C, Ayanian JZ, et al: Understanding cancer patients' experience and outcomes: Development and pilot study of the Cancer Care Outcomes Research and Surveillance patient survey. Support Care Cancer 14:837-848, 2006
5. Ayanian JZ, Zaslavsky AM, Arora NK, et al: Patients' experiences with care for lung cancer and colorectal cancer: Findings from the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol 28:4154-4161, 2010
6. Catalano PJ, Ayanian JZ, Weeks JC, et al: Representativeness of participants in the Cancer Care Outcomes Research and Surveillance Consortium relative to the Surveillance, Epidemiology, and End Results Program. Med Care 51:e9-e15, 2013
7. Weeks JC, Catalano PJ, Cronin A, et al: Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med 367:1616-1625, 2012
8. Zafar SY, Malin JL, Grambow SC, et al: Chemotherapy use and patient treatment preferences in advanced colorectal cancer: A prospective cohort study. Cancer 119:854-862, 2013
9. Piccirillo JF, Costas I: The impact of comorbidity on outcomes. ORL J Otorhinolaryngol Relat Spec 66:180-185, 2004
10. Piccirillo JF, Tierney RM, Costas I, et al: Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291:2441-2447, 2004
11. Pedlow S, Wang Y, O'Muircheartaigh C: The impact of cluster (segment) size on effective sample size. Proc Survey Research Methods Section, Am Stat Assoc 3952-3959, 2005
12. Demidenko E: Sample size determination for logistic regression revisited. Stat Med 26:3385-3397, 2007
13. Demidenko E: Sample size and optimal design for logistic regression with binary interaction. Stat Med 27:36-46, 2008
14. Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128, 2011
15. Yabroff KR, Lund J, Kepka D, et al: Economic burden of cancer in the United States: Estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev 20:2006-2014, 2011
16. Jacobson M, Earle CC, Price M, et al: How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Aff (Millwood) 29:1391-1399, 2010\
17. Jacobson M, Earle CC, Newhouse JP: Geographic variation in physicians' responses to a reimbursement change. N Engl J Med 365:2049-2052, 2011
18. Newhouse JP, Garber AM: Geographic variation in Medicare services. N Engl J Med 368:1465-1468, 2013
19. Brooks GA, Li L, Sharma DB, et al: Regional variation in spending and survival for older adults with advanced cancer. J Natl Cancer Inst 105:634-642, 2013
20. Berenson A: Cancer drug representatives spelled out the way to profit. The New York Times, June 12, 2007
21. Colla CH, Morden NE, Skinner JS, et al: Impact of payment reform on chemotherapy at the end of life. Am J Manag Care 18:e200-e208, 2012
22. Draper DA: Drug pricing: Manufacturer Discounts in the 340b Program Offer Benefits, But Federal Oversight Needs Improvement. Report No. GAO-11-836, September 23, 2011. Washington, DC, US Government Accountability Office
23. Avalere Health: Total cost of cancer care by site of service: Physician office vs. outpatient hospital. Washington DC, Avalere Health, 2012
24. Kocher B, Emanuel EJ: Overcoming the pricing power of hospitals. JAMA 308:1213-1214, 2012